Production (Stage)
Oruka Therapeutics, Inc.
ORKA
$12.58
$0.393.20%
NASDAQ
03/31/2025 | |||||
---|---|---|---|---|---|
Total Cash And Short-Term Investments | 1,158.31% | ||||
Total Receivables | -- | ||||
Inventory | -- | ||||
Prepaid Expenses | -- | ||||
Finance Division Loans and Leases Current | -- | ||||
Total Finance Division Other Current Assets | -- | ||||
Other Current Assets | -- | ||||
Total Current Assets | 1,169.09% | ||||
|
|||||
Total Current Assets | 1,169.09% | ||||
Net Property, Plant & Equipment | -- | ||||
Long-term Investments | -- | ||||
Goodwill | -- | ||||
Total Other Intangibles | -- | ||||
Finance Div Loans & Leases LT | -- | ||||
Total Finance Div Other LT Assets | -- | ||||
Total Other Assets | -78.89% | ||||
Total Assets | 1,235.81% | ||||
|
|||||
Total Accounts Payable | 88,525.00% | ||||
Total Accrued Expenses | -7.92% | ||||
Short-term Debt | -- | ||||
Current Portion of Long-Term Debt/Capital Leases | -- | ||||
Finance Division Debt Current | -- | ||||
Total Finance Division Other Current Liabilities | 1,041.13% | ||||
Total Other Current Liabilities | 1,041.13% | ||||
Total Current Liabilities | 63.61% | ||||
|
|||||
Total Current Liabilities | 63.61% | ||||
Long-Term Debt | -- | ||||
Short-term Debt | -- | ||||
Capital Leases | -- | ||||
Finance Division Debt Non Current | -- | ||||
Total Finance Division Other Non Current Liabilities | -- | ||||
Total Other Liabilities | -- | ||||
Total Liabilities | -61.72% | ||||
|
|||||
Common Stock & APIC | 2,591,694.44% | ||||
Retained Earnings | -1,379.77% | ||||
Treasury Stock & Other | -- | ||||
Total Common Equity | 5,225.29% | ||||
|
|||||
Preferred Stock Redeemable | -- | ||||
Preferred Stock Non Redeemable | -- | ||||
Preferred Stock Convertible | 0.00% | ||||
Preferred Stock, Others | -- | ||||
Total Preferred Equity | 0.00% | ||||
|
|||||
Total Common Equity | 5,225.29% | ||||
Total Preferred Equity | 0.00% | ||||
Total Minority Interest | -- | ||||
Total Equity | 8,935.39% | ||||
|